In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Circulating microRNAs can predict future fatal myocardial infarction in healthy asymptomatic individuals

Session Poster Session III - Friday 08:30 - 12:30

Speaker Anja Bye

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2015

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention
  • Session type : Poster Session

Authors : A Bye (Trondheim,NO), H Roesjoe (Oslo,NO), G Da Silva (Trondheim,NO), T Follestad (Trondheim,NO), J Nauman (Trondheim,NO), T Omland (Oslo,NO), U Wisloeff (Trondheim,NO)

Authors:
A Bye1 , H Roesjoe2 , G Da Silva1 , T Follestad1 , J Nauman1 , T Omland2 , U Wisloeff1 , 1Norwegian University of Science and Technology - Trondheim - Norway , 2Akershus University Hospital - Oslo - Norway ,

On behalf: CERG

Citation:

Background: Cardiovascular disease (CVD) is the predominant cause of morbidity and mortality in developed countries. To manage this pandemic, improved tool for CVD risk prediction, including more sensitive biomarkers is needed. Recently, microRNAs (miRs) have emerged as promising biomarkers of disease, as large amounts of stable miRs can enter the circulation. Previously, increased circulating levels of miR-1 and miR-423 have been associated with myocardial infarction (MI) and heart failure, respectively. This imply that expression profiles of circulating miRs may have potential as a multi-biomarker tool that could offer more sensitive analysis for determination of CVD risk. The main objective of this study was to assess whether circulating miRs can predict future fatal MI in currently healthy individuals.

Methods: This is a retrospective study analyzing participants from the Nord-Trøndelag Health Study part 2 and 3 (HUNT2 and HUNT3). 368 miRs were analyzed in serum samples collected from 112 apparently healthy men and women (40-70 years) without any signs of CVD, where half of them suffered from fatal MI within the next 10 years, and the other half still reported to be healthy 10 years after. The cases and controls were age- and gender matched, and the controls were chosen to ensure no significant differences in BMI, cholesterol, glucose, triglycerides and blood pressure between the groups. 16 candidate miRs from the screening cohort were further analyzed in a new cohort of 50 cases and 50 controls, selected on the same criteria as the screening cohort. DIANA miR-Path software was used to search for pathways associated with the differentially expressed miRs. Logistic regression analyses were performed using SPSS to find the miRs that best predicted future MI.

Results: In the screening cohort, 20 miRs were significantly differentially expressed between the cases and controls (p<0.05). A significant over-representation of miRs associated with cardiac hypertrophy were found among the differentially expressed genes (n=13, p<0.01). Based on the results from the screening cohort, the best prediction model of future MI consisted of a combination of 4 different miRs, providing a sensitivity of 84.2 % and a specificity of 72.7 %. (The results from the validation cohort will be ready in time for the conference.)

Conclusion: The preliminary results from this study suggest that circulating miRs may represent early biomarkers of future MI in apparently healthy individuals.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are